Imperial College London
Portrait Picture

ProfessorIainMcNeish

Faculty of Medicine, Department of Surgery & Cancer

Chair in Oncology
 
 
 
//

Contact

 

+44 (0)20 7594 2185i.mcneish Website

 
 
//

Assistant

 

Ms Sophie Lions +44 (0)20 7594 2792

 
//

Location

 

G036Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Clamp:2019:10.1016/S0140-6736(19)32259-7,
author = {Clamp, AR and James, EC and McNeish, IA and Dean, A and Kim, J-W and O'Donnell, DM and Hook, J and Coyle, C and Blagden, S and Brenton, JD and Naik, R and Perren, T and Sundar, S and Cook, AD and Gopalakrishnan, GS and Gabra, H and Lord, R and Dark, G and Earl, HM and Hall, M and Banerjee, S and Glasspool, RM and Jones, R and Williams, S and Swart, AM and Stenning, S and Parmar, M and Kaplan, R and Ledermann, JA},
doi = {10.1016/S0140-6736(19)32259-7},
journal = {The Lancet},
pages = {2084--2095},
title = {Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial},
url = {http://dx.doi.org/10.1016/S0140-6736(19)32259-7},
volume = {394},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Carboplatin and paclitaxel administered every 3 weeks is standard-of-care first-line chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a significant improvement in progression-free and overall survival with dose-dense weekly paclitaxel and 3-weekly carboplatin. In this study, we aimed to compare efficacy and safety of two dose-dense weekly regimens to standard 3-weekly chemotherapy in a predominantly European population with epithelial ovarian cancer. METHODS: In this phase 3 trial, women with newly diagnosed International Federation of Gynecology and Obstetrics stage IC-IV epithelial ovarian cancer were randomly assigned to group 1 (carboplatin area under the curve [AUC]5 or AUC6 and 175 mg/m2 paclitaxel every 3 weeks), group 2 (carboplatin AUC5 or AUC6 every 3 weeks and 80 mg/m2 paclitaxel weekly), or group 3 (carboplatin AUC2 and 80 mg/m2 paclitaxel weekly). Written informed consent was provided by all women who entered the trial. The protocol had the appropriate national research ethics committee approval for the countries where the study was conducted. Patients entered the trial after immediate primary surgery, or before neoadjuvant chemotherapy with subsequent planned delayed primary surgery. The trial coprimary outcomes were progression-free survival and overall survival. Data analyses were done on an intention-to-treat basis, and were powered to detect a hazard ratio of 0·75 in progression-free survival. The main comparisons were between the control group (group 1) and each of the weekly research groups (groups 2 and 3). FINDINGS: Between June 6, 2011, and Nov 28, 2014, 1566 women were randomly assigned to treatment. 72% (365), completed six protocol-defined treatment cycles in group 1, 60% (305) in group 2, and 63% (322) in group 3, although 90% (454), 89% (454), and 85% (437) completed six platinum-based chemotherapy cycles, respectively. Paclitaxel dose intensification was achieved with weekly treatment (med
AU  - Clamp,AR
AU  - James,EC
AU  - McNeish,IA
AU  - Dean,A
AU  - Kim,J-W
AU  - O'Donnell,DM
AU  - Hook,J
AU  - Coyle,C
AU  - Blagden,S
AU  - Brenton,JD
AU  - Naik,R
AU  - Perren,T
AU  - Sundar,S
AU  - Cook,AD
AU  - Gopalakrishnan,GS
AU  - Gabra,H
AU  - Lord,R
AU  - Dark,G
AU  - Earl,HM
AU  - Hall,M
AU  - Banerjee,S
AU  - Glasspool,RM
AU  - Jones,R
AU  - Williams,S
AU  - Swart,AM
AU  - Stenning,S
AU  - Parmar,M
AU  - Kaplan,R
AU  - Ledermann,JA
DO  - 10.1016/S0140-6736(19)32259-7
EP  - 2095
PY  - 2019///
SN  - 0140-6736
SP  - 2084
TI  - Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
T2  - The Lancet
UR  - http://dx.doi.org/10.1016/S0140-6736(19)32259-7
UR  - https://www.ncbi.nlm.nih.gov/pubmed/31791688
UR  - https://www.sciencedirect.com/science/article/pii/S0140673619322597?via%3Dihub
UR  - http://hdl.handle.net/10044/1/75647
VL  - 394
ER  -
Download